A treatment combining two antibodies against the coronavirus SARS-CoV-2 strongly protected high-risk people with early COVID-19 symptoms from hospitalization and death in an international Phase 2/3 clinical trial.
Joeva Barrow, assistant professor of molecular nutrition in the Division of Nutritional Sciences, has won a 2022 Hartwell Individual Biomedical Research Award, which funds biomedical research to advance children’s health.
Obesity may spur DNA damage in the breast tissue of women who carry BRCA1 or BRCA2 mutations, possibly contributing to breast cancer development in this already high-risk group, according to new multi-institutional translational research led by Weill Cornell Medicine scientists.
The National Institute on Aging of the National Institutes of Health has awarded a grant to Weill Cornell Medicine to develop a screening tool and intervention for elder neglect in patients with Alzheimer’s disease and related dementias.
Metal oxide nanoparticles – commonly used as food coloring and anti-caking agents in commercial ingredients – may damage parts of the human intestine, say Cornell and Binghamton University scientists.
Students and lifelong learners are invited to explore a new interest, enhance their resume or strengthen their professional skills through Cornell’s Fall Part-Time Study Program, which runs Aug. 22 – Dec. 17, 2022. Registration for most students begins August 1.
Culminating a year of planning by the Healthcare Students Association in the Cornell Jeb E. Brooks School of Public Policy's Sloan Program in Health Administration, a case competition attracted 40 teams representing the nation’s top graduate programs in health care and related fields.
Severe COVID-19 infection triggers changes that affect gene expression in immune system stem cells, causing alterations in the body’s immune response, according to a new study by Weill Cornell Medicine and Jackson Laboratory investigators.
A team has identified an antibody that appears to block infection by all dominant variants of the virus that causes COVID-19, including omicron. Their discovery could lead to more potent vaccines and new antibody-based treatments.